90 related articles for article (PubMed ID: 7664799)
1. Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703.
Villadangos JA; Galocha B; García F; Albar JP; López de Castro JA
Eur J Immunol; 1995 Aug; 25(8):2370-7. PubMed ID: 7664799
[TBL] [Abstract][Full Text] [Related]
2. Role of binding pockets for amino-terminal peptide residues in HLA-B27 allorecognition.
Villadangos JA; Galocha B; López D; Calvo V; López de Castro JA
J Immunol; 1992 Jul; 149(2):505-10. PubMed ID: 1378067
[TBL] [Abstract][Full Text] [Related]
3. Overlapping peptide-binding specificities of HLA-B27 and B39: evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies.
Sobao Y; Tsuchiya N; Takiguchi M; Tokunaga K
Arthritis Rheum; 1999 Jan; 42(1):175-81. PubMed ID: 9920028
[TBL] [Abstract][Full Text] [Related]
4. Modulation at multiple anchor positions of the peptide specificity of HLA-B27 subtypes differentially associated with ankylosing spondylitis.
Lamas JR; Paradela A; Roncal F; López de Castro JA
Arthritis Rheum; 1999 Sep; 42(9):1975-85. PubMed ID: 10513815
[TBL] [Abstract][Full Text] [Related]
5. In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain.
el-Zaatari FA; Sams KC; Taurog JD
J Immunol; 1990 Feb; 144(4):1512-7. PubMed ID: 1689355
[TBL] [Abstract][Full Text] [Related]
6. Long-range effects in protein--ligand interactions mediate peptide specificity in the human major histocompatibilty antigen HLA-B27 (B*2701).
Krebs S; Rognan D; López de Castro JA
Protein Sci; 1999 Jul; 8(7):1393-9. PubMed ID: 10422827
[TBL] [Abstract][Full Text] [Related]
7. Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity.
Villadangos JA; Galocha B; López de Castro JA
J Immunol; 1994 Mar; 152(5):2317-23. PubMed ID: 7510742
[TBL] [Abstract][Full Text] [Related]
8. Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides.
Griffin TA; Yuan J; Friede T; Stevanovic S; Ariyoshi K; Rowland-Jones SL; Rammensee HG; Colbert RA
J Immunol; 1997 Nov; 159(10):4887-97. PubMed ID: 9366414
[TBL] [Abstract][Full Text] [Related]
9. HLA-B27: a registry of constitutive peptide ligands.
Lopez de Castro JA; Alvarez I; Marcilla M; Paradela A; Ramos M; Sesma L; Vázquez M
Tissue Antigens; 2004 May; 63(5):424-45. PubMed ID: 15104674
[TBL] [Abstract][Full Text] [Related]
10. Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B.
Rojo S; García F; Villadangos JA; López de Castro JA
J Exp Med; 1993 Mar; 177(3):613-20. PubMed ID: 8436905
[TBL] [Abstract][Full Text] [Related]
11. HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex.
Brooks JM; Colbert RA; Mear JP; Leese AM; Rickinson AB
J Immunol; 1998 Nov; 161(10):5252-9. PubMed ID: 9820497
[TBL] [Abstract][Full Text] [Related]
12. HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket.
García F; Galocha B; Villadangos JA; Lamas JR; Albar JP; Marina A; Lópaz de Castro JA
Tissue Antigens; 1997 Jun; 49(6):580-7. PubMed ID: 9234479
[TBL] [Abstract][Full Text] [Related]
13. B*2707 differs in peptide specificity from B*2705 and B*2704 as much as from HLA-B27 subtypes not associated to spondyloarthritis.
Gómez P; Montserrat V; Marcilla M; Paradela A; de Castro JA
Eur J Immunol; 2006 Jul; 36(7):1867-81. PubMed ID: 16783853
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactive T cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2.
López D; Barber DF; Villadangos JA; López de Castro JA
J Immunol; 1993 Apr; 150(7):2675-86. PubMed ID: 7681078
[TBL] [Abstract][Full Text] [Related]
15. Peptide presentation to an alloreactive CTL clone is modulated through multiple mechanisms involving polymorphic and conserved residues in HLA-B27.
García-Peydró M; Paradela A; Lamas JR; López De Castro JA
J Immunol; 1999 Dec; 163(11):6060-4. PubMed ID: 10570294
[TBL] [Abstract][Full Text] [Related]
16. Structure and diversity of HLA-B27-specific T cell epitopes. Analysis with site-directed mutants mimicking HLA-B27 subtype polymorphism.
Calvo V; Rojo S; López D; Galocha B; López de Castro JA
J Immunol; 1990 May; 144(10):4038-45. PubMed ID: 1692072
[TBL] [Abstract][Full Text] [Related]
17. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies.
Mear JP; Schreiber KL; Münz C; Zhu X; Stevanović S; Rammensee HG; Rowland-Jones SL; Colbert RA
J Immunol; 1999 Dec; 163(12):6665-70. PubMed ID: 10586062
[TBL] [Abstract][Full Text] [Related]
18. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies.
Boisgérault F; Tieng V; Stolzenberg MC; Dulphy N; Khalil I; Tamouza R; Charron D; Toubert A
J Clin Invest; 1996 Dec; 98(12):2764-70. PubMed ID: 8981922
[TBL] [Abstract][Full Text] [Related]
19. Extended repertoire of permissible peptide ligands for HLA-B*2702.
Raghavan M; Lebrón JA; Johnson JL; Bjorkman PJ
Protein Sci; 1996 Oct; 5(10):2080-8. PubMed ID: 8897608
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactivity among evolutionarily distant major histocompatibility complex class I molecules (HLA-B27 and H-2Kk) revealed by xenoreactive T lymphocytes.
Frangoulis B; Reboul M; Rocca A; Pla M
Eur J Immunol; 1993 Feb; 23(2):338-42. PubMed ID: 8436169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
